Related Experiment Video
Updated: Jun 29, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
High SEC61A1 expression predicts poor outcome of acute myeloid leukemia
Guo Ji1, Xiaofei Yang2, Jun Li3,4
1Department of Hematology, Taixing People's Hospital, Taixing, 225400, Jiangsu, China.
Open Medicine (Warsaw, Poland)
|April 8, 2024
Summary
Elevated SEC61A1 expression is linked to poor survival in acute myeloid leukemia (AML) patients. This study identifies SEC61A1 as a potential prognostic biomarker and therapeutic target for AML.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- The role of SEC61A1 in cancer is known, but its specific involvement in acute myeloid leukemia (AML) is unclear.
- SEC61A1 is a component of the Sec61 translocon, crucial for protein translocation across membranes.
Purpose of the Study:
- To investigate the role and prognostic significance of SEC61A1 in acute myeloid leukemia (AML).
- To evaluate SEC61A1 as a potential therapeutic target in AML.
Main Methods:
- Bioinformatic analyses including gene expression profiling and proteomic analysis.
- In vitro validation using SEC61A1 knockdown in cell lines and quantitative reverse transcription PCR (RT-qPCR).
Main Results:
- SEC61A1 expression was significantly upregulated in AML patients compared to healthy controls.
- Higher SEC61A1 expression correlated with reduced overall survival in AML patients.
- SEC61A1 was identified as an independent risk factor for survival in AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- High SEC61A1 expression was associated with enhanced cell growth signaling pathways.
Conclusions:
- SEC61A1 is a potential prognostic biomarker for predicting survival in AML patients.
- SEC61A1 represents a promising therapeutic target for AML treatment.
